ATE491704T1 - 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten - Google Patents

4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten

Info

Publication number
ATE491704T1
ATE491704T1 AT05738662T AT05738662T ATE491704T1 AT E491704 T1 ATE491704 T1 AT E491704T1 AT 05738662 T AT05738662 T AT 05738662T AT 05738662 T AT05738662 T AT 05738662T AT E491704 T1 ATE491704 T1 AT E491704T1
Authority
AT
Austria
Prior art keywords
map kinase
ylü
cycloalkylamino
imidazoline
pyrimidine
Prior art date
Application number
AT05738662T
Other languages
English (en)
Inventor
Akira Kubo
Tetsu Nakane
Tatsuo Nakajima
Takanori Murakami
Hidetaka Miyoshi
Akihito Ogasawara
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Application granted granted Critical
Publication of ATE491704T1 publication Critical patent/ATE491704T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05738662T 2004-04-28 2005-04-28 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten ATE491704T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2004133204 2004-04-28
US56608904P 2004-04-29 2004-04-29
JP2005007832 2005-01-14
PCT/JP2005/008564 WO2005105790A1 (en) 2004-04-28 2005-04-28 4- 2- (cycloalkylamino) pyrimidin-4-yl ! - (phenyl) - imidazolin-2- one derivatives as p38 map- kinase inhibitors for the treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
ATE491704T1 true ATE491704T1 (de) 2011-01-15

Family

ID=43384198

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05738662T ATE491704T1 (de) 2004-04-28 2005-04-28 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten

Country Status (12)

Country Link
US (1) US7700771B2 (de)
EP (1) EP1740578B1 (de)
JP (1) JP2007535476A (de)
AT (1) ATE491704T1 (de)
AU (1) AU2005238390C1 (de)
BR (1) BRPI0510335A (de)
CA (1) CA2563042C (de)
DE (1) DE602005025332D1 (de)
MY (1) MY143245A (de)
NO (1) NO20064175L (de)
TW (1) TWI326282B (de)
WO (1) WO2005105790A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113481A1 (en) 2003-12-17 2010-05-06 Alcon Research, Ltd. Use of serum amyloid a gene in diagnosis and treatment of glaucoma and identification of anti-glaucoma agents
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
UA114410C2 (uk) * 2011-10-06 2017-06-12 Байєр Інтеллектуал Проперті Гмбх Гетероциклілпіри(mi)динілпіразол
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
JP7268049B2 (ja) 2018-03-08 2023-05-02 インサイト・コーポレイション PI3K-γ阻害剤としてのアミノピラジンジオール化合物
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
US11993580B1 (en) 2022-12-02 2024-05-28 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658903A (en) 1995-06-07 1997-08-19 Smithkline Beecham Corporation Imidazole compounds, compositions and use
AR016294A1 (es) * 1997-07-02 2001-07-04 Smithkline Beecham Corp Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
JP2001519381A (ja) 1997-10-10 2001-10-23 インペリアル・カレッジ・イノベイションズ・リミテッド 子宮収縮管理のためのcsaidtm化合物の使用
CO5170501A1 (es) * 1999-04-14 2002-06-27 Novartis Ag AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
AU6909600A (en) * 1999-08-13 2001-03-13 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
WO2001091749A1 (en) 2000-06-01 2001-12-06 Merck & Co., Inc. Use of (di-substituted-phenyl)-pyrimidinyl-imidazole derivatives as jnk-inhibitors
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
PL210470B1 (pl) 2001-10-22 2012-01-31 Mitsubishi Tanabe Pharma Corp Związki 4-imidazolin-2-onu i jego zastosowanie
MXPA04011638A (es) * 2002-06-05 2005-03-07 Pharmacia Corp Derivados de pirazol como inhibidores de la quinasa p38.
JP2005529493A (ja) 2002-06-06 2005-09-29 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 半導体デバイスを有するノンリードクワッドフラットパッケージ
MXPA05012377A (es) * 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.

Also Published As

Publication number Publication date
NO20064175L (no) 2006-12-13
MY143245A (en) 2011-04-15
US7700771B2 (en) 2010-04-20
TW200536843A (en) 2005-11-16
CA2563042C (en) 2010-04-27
CA2563042A1 (en) 2005-11-10
AU2005238390B2 (en) 2009-01-08
EP1740578B1 (de) 2010-12-15
US20070185326A1 (en) 2007-08-09
DE602005025332D1 (de) 2011-01-27
WO2005105790A1 (en) 2005-11-10
JP2007535476A (ja) 2007-12-06
AU2005238390A1 (en) 2005-11-10
EP1740578A1 (de) 2007-01-10
AU2005238390C1 (en) 2009-06-25
BRPI0510335A (pt) 2007-10-23
TWI326282B (en) 2010-06-21

Similar Documents

Publication Publication Date Title
ATE491704T1 (de) 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten
JO2791B1 (en) Acid secretion inhibitor
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
EA200870358A1 (ru) 2-(циклический амино) пиримидоновые производные в качестве ингибиторов tpk1
TW200740820A (en) Fused heterocyclic derivatives and use thereof
TW200633991A (en) Chemical compounds
BRPI0506817A (pt) inibidores seletivos de quinase
ATE479667T1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
AR053662A1 (es) Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
DE602005009209D1 (de) Zur behandlung von entzündungen geeignete indole
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
EA200700141A1 (ru) Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
EA200601358A1 (ru) Новые ингибиторы химазы
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
NO20065537L (no) Heterosykliske amidforbindelser og anvendelse derav som en MMP-13-inhibitor
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
ATE553077T1 (de) Peptidaseinhibitoren
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
PE20020524A1 (es) 7-oxo-piridopirimidinas como inhibidores de quinasas
CO5680420A2 (es) Compuestos de 6-amino-1h-indazol y 4-aminobenzenofurano como inhibidores de la fosfodiesterasa 4
DE502006008710D1 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
TW200616997A (en) The preparation method for 6-substituted-1-methyl-1h-benzoimidazol derivatives and their preparation imtermediates
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties